Details for Patent: 5,608,072
✉ Email this page to a colleague
Title: | Retroviral protease inhibiting compounds |
Abstract: | A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed. |
Inventor(s): | Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing L. (Gurnee, IL), Zhao; Chen (Gurnee, IL) |
Assignee: | Abbott Laboratories (Abbott Park, IL) |
Filing Date: | Apr 04, 1995 |
Application Number: | 08/416,259 |
Claims: | 1. A compound of the formula: ##STR18## wherein R.sub.1 is monosubstituted isoxazolyl or monosubstituted isothiazolyl wherein the substituent is selected from (i) C.sub.1 -to-C.sub.6 -loweralkyl, (ii) C.sub.2 -to-C.sub.6 -loweralkenyl, (iii) C.sub.3 -to-C.sub.7 -cycloalkyl, (iv) C.sub.3 -to-C.sub.7 -cycloalkyl-C.sub.1 -to-C.sub.6 -alkyl, (v) C.sub.5 -to-C.sub.7 -cycloalkenyl, (vi) C.sub.5 -to-C.sub.7 -cycloalkenyl-C.sub.1 -to-C.sub.6 -alkyl, (vii) C.sub.1 -to-C.sub.6 -alkoxy-C.sub.1 -to-C.sub.6 -alkyl or benzyloxy-C.sub.1 -to-C.sub.6 -alkyl, (viii) C.sub.1 -to-C.sub.6 -thioalkoxy-C.sub.1 -to-C.sub.6 -alkyl or benzyl-S-C.sub.1 -to-C.sub.6 -alkyl, (ix) C.sub.1 -to-C.sub.6 -alkylamino, (x) di-C.sub.1 -to-C.sub.6 -alkylamino, (xi) phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, C.sub.1 -to-C.sub.6 -loweralkyl, hydroxy, C.sub.1 -to-C.sub.6 -alkoxy, benzyloxy, benzyl-S- and thioalkoxy, (xii)phenyl-C.sub.1 -to-C.sub.6 -alkyl wherein the phenyl ring is unsubstituted or substituted as defined above, (xiii)di-C.sub.1 -to-C.sub.6 -alkylamino-C.sub.1 -to-C.sub.6 -alkyl, (xiv) C.sub.1 -to-C.sub.6 -alkoxy or benzyloxy and (xv) C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S-; n is 1, 2 or 3; R.sub.2 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl; R.sub.3 is C.sub.1 -to-C.sub.6 -loweralkyl; R.sub.4 and R.sub.4a are independently selected from phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from (i) halo, (ii) C.sub.1 -to-C.sub.6 -loweralkyl, (iii) hydroxy, (iv) C.sub.1 -to-C.sub.6 -alkoxy or benzyloxy and (v) C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S-; R.sub.6 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl; R.sub.7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted or substituted with C.sub.1 -to-C.sub.6 -loweralkyl; X is hydrogen and Y is --OH; and Z is absent, --O--, --S--, --CH.sub.2 -- or --N(R.sub.8)-- wherein R.sub.8 is C.sub.1 -to-C.sub.6 -loweralkyl, C.sub.3 -to-C.sub.7 -cycloalkyl, --OH or --NHR.sub.8a wherein R.sub.8a is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl; or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 wherein n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen and R.sub.7 is thiazolyl or oxazolyl. 3. The compound of claim 1 n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen and R.sub.7 is 5-thiazolyl or 5-oxazolyl. 4. The compound of claim 1 wherein R.sub.1 is monosubstituted isoxazolyl or monosubstituted isothiazolyl wherein the substituent is C.sub.1 -to-C.sub.6 -loweralkyl; n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --O-- or --N(R.sub.8)-- wherein R.sub.8 is C.sub.1 -to-C.sub.6 -loweralkyl. 5. The compound of claim 1 wherein R.sub.1 is monosubstituted isoxazolyl or monosubstituted isothiazolyl wherein the substituent is ethyl or isopropyl; n is 1; R.sub.2 is hydrogen; R.sub.3 is methyl or isopropyl; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --O--. 6. The compound of claim 1 wherein R.sub.1 is monosubstituted isoxazolyl or monosubstituted isothiazolyl wherein the substituent is ethyl or isopropyl; n is 1; R.sub.2 is hydrogen; R.sub.3 is isopropyl; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --N(R.sub.8)-- wherein R.sub.8 is methyl. 7. A compound selected from the group consisting of: (2S,3S,5S)-5-(N-(N-((3-Isopropyl-5-isoxazolyl)methoxycarbonyl)valinyl)amino )-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; and (2S,3S,5S)-5-(N-(N-((3-Isopropyl-5-isoxazolyl)methoxycarbonyl)valinyl)amino )-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; or a pharmaceutically acceptable salt thereof. 8. A compound of the formula: ##STR19## wherein R.sub.1 is monosubstituted isoxazolyl or monosubstituted isothiazolyl wherein the substituent is selected from (i) C.sub.1 -to-C.sub.6 -loweralkyl, (ii) C.sub.2 -to-C.sub.6 -loweralkenyl, (iii) C.sub.3 -to-C.sub.7 -cycloalkyl, (iv) C.sub.3 -to-C.sub.7 -cycloalkyl-C.sub.1 -to-C.sub.6 -alkyl, (v) C.sub.5 -to-C.sub.7 -cycloalkenyl, (vi) C.sub.5 -to-C.sub.7 -cycloalkenyl-C.sub.1 -to-C.sub.6 -alkyl, (vii) C.sub.1 -to-C.sub.6 -alkoxy-C.sub.1 -to-C.sub.6 -alkyl or benzyloxy-C.sub.1 -to-C.sub.6 -alkyl, (viii) C.sub.1 -to-C.sub.6 -thioalkoxy-C.sub.1 -to-C.sub.6 -alkyl or benzyl-S-C.sub.1 -to-C.sub.6 -alkyl, (ix) C.sub.1 -to-C.sub.6 -alkylamino, (x) di-C.sub.1 -to-C.sub.6 -alkylamino, (xi) phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, C.sub.1 -to-C.sub.6 -loweralkyl, hydroxy, C.sub.1 -to-C.sub.6 -alkoxy, benzyloxy, benzyl-S- and thioalkoxy, (xii) phenyl-C.sub.1 -to-C.sub.6 -alkyl wherein the phenyl ring is unsubstituted or substituted as defined above, (xiii) di-C.sub.1 -to-C.sub.6 -alkylamino-C.sub.1 -to-C.sub.6 -alkyl, (xiv) C.sub.1 -to-C.sub.6 -alkoxy or benzyloxy and (xv) C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S-; n is 1, 2 or 3; R.sub.2 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl; R.sub.4 and R.sub.4a are independently selected from phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from (i) halo, (ii) C.sub.1 -to-C.sub.6 -loweralkyl, (iii) hydroxy, (iv) C.sub.1 -to-C.sub.6 -alkoxy or benzyloxy and (v) C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S-; R.sub.6 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl; R.sub.7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted and R.sub.3 is C.sub.2 -to-C.sub.6 -loweralkyl and Z is absent, --O--, --S-- or --CH.sub.2 --; or R.sub.7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is substituted with C.sub.1 -to-C.sub.6 -loweralkyl and R.sub.3 is C.sub.1 -to-C.sub.6 -loweralkyl and Z is absent, --O--, --S--, --CH.sub.2 -- or --N(R.sub.8)-- wherein R.sub.8 is C.sub.1 -to-C.sub.6 -loweralkyl, C.sub.3 -to-C.sub.7 -cycloalkyl, --OH or --NHR.sub.8a wherein R.sub.8a is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl; and X is --OH and Y is hydrogen; or a pharmaceutically acceptable salt thereof. 9. The compound of claim 8 wherein n is 1; R.sub.2 is hydrogen; R.sub. is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen and R.sub.7 is thiazolyl or oxazolyl. 10. The compound of claim 8 wherein n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen and R.sub.7 is 5-thiazolyl or 5-oxazolyl. 11. The compound of claim 8 wherein n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --O--. 12. The compound of claim 8 wherein n is 1; R.sub.2 is hydrogen; R.sub.3 is methyl or isopropyl; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --O--. |